{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:25:04Z","timestamp":1791638704414,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tampere University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Angiogenesis is crucial for tumor development, progression, and metastasizing. The most important regulator of angiogenesis is the vascular endothelial growth factor (VEGF) family, which is involved in multiple pathways in tumor microenvironment. The objective of this study was to investigate the prognostic value of the VEGF family in patients treated for metastatic breast cancer. The emphasis was on neuropilin-1 (NRP-1) and placental growth factor (PlGF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>An analysis of eight members of the VEGF family was performed using baseline plasma samples of 65 patients treated for metastatic HER2 negative breast cancer in a phase II first-line bevacizumab plus chemotherapy trial. The patients were divided into two groups, high or low, according to the median for each VEGF family member. Progression-free survival (PFS) and overall survival (OS) were determined for each VEGF family member.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients with low plasma levels of NRP-1 and PlGF had a longer OS than those with high plasma levels [multivariable adjusted hazard ratios (HRs) 2.54 (95% confidence interval (CI) 1.11\u20135.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and 3.11 (95% CI 1.30\u20137.47, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), respectively]. The patients with low levels of both NRP-1 and PlGF had a remarkably long OS with HR of 6.24, (95% CI 1.97\u201319.76, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). In addition, high baseline NRP-1 level was associated with a significantly shorter PFS [multivariable adjusted HR 2.90 (95% CI 1.02\u20138.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.04)] than that in the low-level group, and a high baseline vascular endothelial growth factor receptor-2 level was associated with a longer PFS [multivariable adjusted HR 0.43 (95% CI 0.19\u20130.98, <jats:italic>p<\/jats:italic>\u2009=\u20090.04)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Especially NRP-1 and PlGF have prognostic potential in metastatic breast cancer patients treated with a bevacizumab-taxane combination. Patients with low plasma levels of NRP-1 or PlGF have longer OS than patients with high levels. Patients with both low NRP-1 and PlGF levels appear to have excellent long-term survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier: NCT00979641, registration date 18\/09\/2009. The regional Ethics Committee: R08142M, registration date 18\/11\/2008.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12070-7","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:02:00Z","timestamp":1710176520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Niina","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Tiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"H\u00e4m\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Luukkaala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Lahdenper\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Vihinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirkko-Liisa","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeva","family":"Moilanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"7","key":"12070_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ctrv.2012.04.006","volume":"38","author":"PM Hoff","year":"2012","unstructured":"Hoff PM, Machado KK. Role of angiogenesis in the pathogenesis of cancer. Cancer Treat Rev. 2012;38(7):825\u201333.","journal-title":"Cancer Treat Rev"},{"issue":"7347","key":"12070_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298\u2013307.","journal-title":"Nature"},{"issue":"5","key":"12070_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/1535-7163.MCT-05-0538","volume":"5","author":"LM Ellis","year":"2006","unstructured":"Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther. 2006;5(5):1099\u2013107.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"12070_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.yexcr.2005.11.024","volume":"312","author":"DR Bielenberg","year":"2006","unstructured":"Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res. 2006;312(5):584\u201393.","journal-title":"Exp Cell Res"},{"key":"12070_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-35582-1_3","volume":"1223","author":"S Niland","year":"2020","unstructured":"Niland S, Eble JA, Neuropilin. Handyman and Power Broker in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1223:31\u201367.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"12070_CR6","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1073\/pnas.040337597","volume":"97","author":"ML Gagnon","year":"2000","unstructured":"Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci U S A. 2000;97(6):2573\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"12070_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/geno.2000.6381","volume":"70","author":"M Rossignol","year":"2000","unstructured":"Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics. 2000;70(2):211\u201322.","journal-title":"Genomics"},{"key":"12070_CR8","doi-asserted-by":"crossref","unstructured":"Albonici L, Giganti MG, Modesti A, Manzari V, Bei R. Multifaceted role of the placental growth factor (PlGF) in the Antitumor Immune Response and Cancer Progression. Int J Mol Sci. 2019;20(12).","DOI":"10.3390\/ijms20122970"},{"issue":"1","key":"12070_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-012-1957-0","volume":"133","author":"E Maae","year":"2012","unstructured":"Maae E, Olsen DA, Steffensen KD, Jakobsen EH, Brandslund I, S\u00f8rensen FB, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat. 2012;133(1):257\u201365.","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"12070_CR10","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1016\/j.ejca.2005.07.022","volume":"41","author":"C Parr","year":"2005","unstructured":"Parr C, Watkins G, Boulton M, Cai J, Jiang WG. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer. 2005;41(18):2819\u201327.","journal-title":"Eur J Cancer"},{"key":"12070_CR11","doi-asserted-by":"crossref","unstructured":"Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med. 2012;2(8).","DOI":"10.1101\/cshperspect.a011056"},{"issue":"12","key":"12070_CR12","doi-asserted-by":"publisher","first-page":"6431","DOI":"10.21873\/anticanres.11241","volume":"36","author":"L Tiainen","year":"2016","unstructured":"Tiainen L, Tanner M, Lahdenper\u00e4 O, Vihinen P, Jukkola A, Karihtala P, et al. Bevacizumab Combined with Docetaxel or Paclitaxel as First-line treatment of HER2-negative metastatic breast Cancer. Anticancer Res. 2016;36(12):6431\u20138.","journal-title":"Anticancer Res"},{"issue":"1","key":"12070_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-019-5959-8","volume":"19","author":"L Tiainen","year":"2019","unstructured":"Tiainen L, Korhonen EA, Lepp\u00e4nen V-M, Luukkaala T, H\u00e4m\u00e4l\u00e4inen M, Tanner M, et al. High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer. 2019;19(1):732.","journal-title":"BMC Cancer"},{"key":"12070_CR14","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2021.003","volume-title":"Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma","author":"M Cechova","year":"2021","unstructured":"Cechova M, Chocholaty M, Babjuk M, Zima T, Havlova K, Koldova M, et al. Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma. Czechoslov: Biomed Pap Med Fac Univ Palacky, Olomouc; 2021."},{"issue":"5","key":"12070_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.oraloncology.2011.12.007","volume":"48","author":"S-J Cheng","year":"2012","unstructured":"Cheng S-J, Lee J-J, Cheng S-L, Chen H-M, Chang H-H, Wang Y-P, et al. Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma. Oral Oncol. 2012;48(5):424\u20138.","journal-title":"Oral Oncol"},{"issue":"2","key":"12070_CR16","first-page":"537","volume":"23","author":"A Escudero-Esparza","year":"2010","unstructured":"Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep. 2010;23(2):537\u201344.","journal-title":"Oncol Rep"},{"issue":"4","key":"12070_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1620\/tjem.244.291","volume":"244","author":"Q Meng","year":"2018","unstructured":"Meng Q, Duan P, Li L, Miao Y. Expression of Placenta Growth factor is Associated with unfavorable prognosis of Advanced-Stage Serous Ovarian Cancer. Tohoku J Exp Med. 2018;244(4):291\u20136.","journal-title":"Tohoku J Exp Med"},{"issue":"2","key":"12070_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12253-015-0003-z","volume":"22","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu P, Jiang Y, Dou X, Yan J, Ma C, et al. High expression of Neuropilin-1 associates with unfavorable clinicopathological features in Hepatocellular Carcinoma. Pathol Oncol Res. 2016;22(2):367\u201375.","journal-title":"Pathol Oncol Res"},{"key":"12070_CR19","doi-asserted-by":"crossref","unstructured":"Rachner TD, Kasimir-Bauer S, Goebel A, Erdmann K, Hoffmann O, Rauner M et al. Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. J Cancer Res Clin Oncol. 2021.","DOI":"10.1007\/s00432-021-03635-1"},{"issue":"1","key":"12070_CR20","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41598-017-03280-0","volume":"7","author":"A Naik","year":"2017","unstructured":"Naik A, Al-Zeheimi N, Bakheit CS, Al Riyami M, Al Jarrah A, Al Moundhri MS, et al. Neuropilin-1 Associated molecules in the blood distinguish poor prognosis breast Cancer: a cross-sectional study. Sci Rep. 2017;7(1):3301.","journal-title":"Sci Rep"},{"issue":"6","key":"12070_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4149\/neo_2020_191127N1223","volume":"67","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang YN, Xu DQ, Huang JG, Lv D, Shi XY, et al. Neuropilin1, a novel independent prognostic factor and therapeutic target in triple-negative breast cancer. Neoplasma. 2020;67(6):1335\u201342.","journal-title":"Neoplasma"},{"key":"12070_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fonc.2019.00323","volume":"9","author":"N Al-Zeheimi","year":"2019","unstructured":"Al-Zeheimi N, Naik A, Bakheit CS, Al Riyami M, Al Ajarrah A, Al Badi S, et al. Neoadjuvant Chemotherapy alters Neuropilin-1, PlGF, and SNAI1 expression levels and predicts breast Cancer patients response. Front Oncol. 2019;9:323.","journal-title":"Front Oncol"},{"issue":"9","key":"12070_CR23","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1172\/JCI99257","volume":"128","author":"S Rizzolio","year":"2018","unstructured":"Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, et al. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. J Clin Invest. 2018;128(9):3976\u201390.","journal-title":"J Clin Invest"},{"issue":"1","key":"12070_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan Q, Chanthery Y, Liang W-C, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11(1):53\u201367.","journal-title":"Cancer Cell"},{"issue":"12","key":"12070_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(10)70232-1","volume":"11","author":"AM Jubb","year":"2010","unstructured":"Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172\u201383.","journal-title":"Lancet Oncol"},{"issue":"5","key":"12070_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/bjc.2013.69","volume":"108","author":"DW Miles","year":"2013","unstructured":"Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052\u201360.","journal-title":"Br J Cancer"},{"issue":"10","key":"12070_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","volume":"14","author":"D Cameron","year":"2013","unstructured":"Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933\u201342.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12070-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:03:57Z","timestamp":1710176637000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12070"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12070-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Tampere University Hospital approved the original phase II clinical trial protocol (R08142M). The trial identifier is NCT00979641. All the patients that participated in the study gave their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.M. has received funding (grants) from Tampere University Hospital. L.T., M.T., P.K. and A.J. participated in an industry-sponsored clinical trial supported by Roche. P.K. is a member in an advisory board for Roche. A.J. is a member in an advisory board for Lilly. O.L. reports being consultant for Herantis Pharma. P.V. has received research funding from Eschner\u00b4s Foundation, consulting or advisory honoraria from Merck, Bristol-Myers Squibb, Ipsen, Novartis, and Roche, speakers\u2019 bureau honoraria from Merck, Roche, and Bristol-Myers Squibb. M.H., T.L., P-L.K-L. and E.M. have no conflict of interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}